Q-omics provides the consensus-scored N4BP2L2-IT2 profile across patient tissues and cancer cell-line models. N4BP2L2-IT2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, N4BP2L2-IT2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, N4BP2L2-IT2 RNA expression shows 19,670 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where N4BP2L2-IT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for N4BP2L2-IT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes N4BP2L2-IT2 survival associations across molecular data types. N4BP2L2-IT2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible N4BP2L2-IT2 RNA expression–survival associations across cancer types. High N4BP2L2-IT2 expression shows unfavorable associations in KIRC, ACC, LIHC, UVM and CESC, but favorable associations in READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for N4BP2L2-IT2 RNA expression.
This table summarizes N4BP2L2-IT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for N4BP2L2-IT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. N4BP2L2-IT2 shows lower tumor expression in BRCA and UCEC and higher tumor expression in KIRC, BLCA, LIHC and CHOL. The KIRC box plot shows higher N4BP2L2-IT2 RNA expression in tumor versus normal tissue (log2 FC = +0.459, t-test p < 0.001).
This table shows molecular features associated with N4BP2L2-IT2 in patient tissues and cancer cell lines. In patient samples, N4BP2L2-IT2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, N4BP2L2-IT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
